Eurofins Scientific Investors Need More than Profitability Improvement

Dow Jones09-29 15:12

0712 GMT - Eurofins Scientific's 2027 target of an improvement in profitability seems firmly within reach, but this is no longer enough as the debate among investors shifts back to growth, Bernstein analysts say in a research note. The French lab-testing company has historically delivered sustainable organic sales growth above 6%, but its growth engine now appears structurally weaker, the analysts say. Eurofins is heavily exposed to Europe, where clinical and research-and-development activity remains weak, and this might explain why organic growth in its biopharma business has remained subdued for the past two years, they add. Bernstein cuts its recommendation on Eurofins stock to market perform from outperform, and trims its target price to 73.90 euros from 77.20 euros. Shares fall 2.1% to 77.08 euros.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2671999942?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-29 15:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2671999942","market":"sg","top_or_hot":-1,"title":"Eurofins Scientific Investors Need More than Profitability Improvement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>0712 GMT - Eurofins Scientific's 2027 target of an improvement in profitability seems firmly within reach, but this is no longer enough as the debate among investors shifts back to growth, Bernstein analysts say in a research note. The French lab-testing company has historically delivered sustainable organic sales growth above 6%, but its growth engine now appears structurally weaker, the analysts say. Eurofins is heavily exposed to Europe, where clinical and research-and-development activity remains weak, and this might explain why organic growth in its biopharma business has remained subdued for the past two years, they add. Bernstein cuts its recommendation on Eurofins stock to market perform from outperform, and trims its target price to 73.90 euros from 77.20 euros. Shares fall 2.1% to 77.08 euros.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eurofins Scientific Investors Need More than Profitability Improvement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEurofins Scientific Investors Need More than Profitability Improvement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-09-29 15:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>0712 GMT - Eurofins Scientific's 2027 target of an improvement in profitability seems firmly within reach, but this is no longer enough as the debate among investors shifts back to growth, Bernstein analysts say in a research note. The French lab-testing company has historically delivered sustainable organic sales growth above 6%, but its growth engine now appears structurally weaker, the analysts say. Eurofins is heavily exposed to Europe, where clinical and research-and-development activity remains weak, and this might explain why organic growth in its biopharma business has remained subdued for the past two years, they add. Bernstein cuts its recommendation on Eurofins stock to market perform from outperform, and trims its target price to 73.90 euros from 77.20 euros. Shares fall 2.1% to 77.08 euros.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISBC","symbol_name":"投资者银行","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2671999942","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2671999942","pubTimestamp":1790665920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0712 GMT - Eurofins Scientific's 2027 target of an improvement in profitability seems firmly within reach, but this is no longer enough as the debate among investors shifts back to growth, Bernstein analysts say in a research note. The French lab-testing company has historically delivered sustainable organic sales growth above 6%, but its growth engine now appears structurally weaker, the analysts say. Eurofins is heavily exposed to Europe, where clinical and research-and-development activity remains weak, and this might explain why organic growth in its biopharma business has remained subdued for the past two years, they add. Bernstein cuts its recommendation on Eurofins stock to market perform from outperform, and trims its target price to 73.90 euros from 77.20 euros. Shares fall 2.1% to 77.08 euros.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISBC":"投资者银行","BK4211":"区域性银行"},"translate_title":"Eurofins 科学投资者需要的不仅仅是提高盈利能力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5},"content_text":"0712 GMT - Eurofins Scientific's 2027 target of an improvement in profitability seems firmly within reach, but this is no longer enough as the debate among investors shifts back to growth, Bernstein analysts say in a research note. The French lab-testing company has historically delivered sustainable organic sales growth above 6%, but its growth engine now appears structurally weaker, the analysts say. Eurofins is heavily exposed to Europe, where clinical and research-and-development activity remains weak, and this might explain why organic growth in its biopharma business has remained subdued for the past two years, they add. Bernstein cuts its recommendation on Eurofins stock to market perform from outperform, and trims its target price to 73.90 euros from 77.20 euros. Shares fall 2.1% to 77.08 euros.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2671999942","isCrawlerRequest":true}